Notice of Proposed Sale · 144
CareDx, Inc.
CDNANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CAREDX, INC.
- Issuer CIK
- 0001217234
- SEC file number
- 001-36536
- Phone
- 415-287-2300
- Person for whose account securities are to be sold
- PETER MAAG
- Relationships to issuer
- Director
- Street
- 8000 Marina Boulevard,
- City
- Brisbane
- State / country code
- CA
- Postal code
- 94005
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 46,963 | 2,178,945.34 | 51,734,223 | 08/05/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 02/03/2025 | Restricted Stock | Issuer | 3,268 | N | 02/03/2025 | Not Applicable |
| Common | 06/14/2025 | Restricted Stock | Issuer | 10,570 | N | 06/14/2025 | Not Applicable |
| Common | 08/05/2026 | Stock Option Exercise | Issuer | 33,125 | N | 08/05/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| PETER MAAG | Common | 08/04/2026 | 75,653 | 3,576,851.19 |
Seller — prior-sale row 1, entry 1
- Name
- PETER MAAG
- Street
- 8000 Marina Boulevard,
- City
- Brisbane
- State / country code
- CA
- Postal code
- 94005
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/05/2026
- Signed
- /s/ Peter Maag
Company context
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics based information for transplant patients. For more information, please visit www.caredx.com.